SB
VBIV

Strategic Blueprint’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Strategic Blueprint’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-408
Closed -$10K – 544
2022
Q2 		$10K Sell
408
-234
-36% -$7.96K ﹤0.01% 494
2022
Q1 		$32K Buy
+642
New +$31.7K ﹤0.01% 495

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Strategic Blueprint's VBIV Position: Q3 2022 in Review

Strategic Blueprint sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2022, closing a stake of 408 shares — an estimated $10K sold.

Strategic Blueprint first reported a position in VBIV in Q1 2022 and held it in 2 quarters. The position peaked at $32K in Q1 2022. 127 funds tracked by Wall St. Rank hold VBIV as of Q3 2022.

  • Strategic Blueprint reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2022 after selling out during the quarter.
  • Strategic Blueprint sold 408 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2022, an estimated $10K.
  • Strategic Blueprint first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2022 and held it in 2 quarters.
  • Strategic Blueprint's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $32K in Q1 2022.
  • 127 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2022.

Based on Strategic Blueprint's 13F filing for Q3 2022, filed 8 Nov 2022.